Thrombophilia is a group of disorders in which blood has an increased tendency to clot. It may be caused by inherited or acquired conditions. Secondary disorders include heparin-induced thrombocytopenia, antiphospholipid antibody syndrome, neoplasia, oral contraceptive use, obesity, smoking and surgery. Primary disorders or genetic causes of thrombophilia include factor V Leiden mutation, deficiency of antithrombin III, protein C or S, histidine-rich glycoprotein deficiency and prothrombin-related thrombophilia.

Thrombophilia is associated with risk of deep venous thrombosis and/or venous thromboembolism. Sometimes the thrombosis occurs in uncommon sites, such as the splanchnic veins, cerebral veins and retinal vein, however the clinical expression of hereditary thrombophilia is variable. Some individuals never develop thrombosis, others may remain asymptomatic until adulthood and others have recurrent thromboembolism before 30 years of age.

Factor V Leiden thrombophilia is the most common inherited form of thrombophilia. The prevalence in the US and European general populations is 3-8% for one copy of the factor V Leiden mutation; about 1:5000 persons have two copies of the mutation ([@ref1]). Moderate protein S deficiency is estimated to affect 1:500 individuals. Severe deficiency is rare and its prevalence is unknown ([@ref2]). Moderate protein C deficiency affects about 1:500 individuals. Severe deficiency occurs in about 1:4000000 newborns ([@ref2]). Prothrombin-related thrombophilia is the second most common genetic form of thrombophilia, occurring in about 1.7-3% of the European and US general populations ([@ref3]). Hereditary antithrombin III deficiency has a prevalence of 1:500-5000 in the general population ([@ref4]).

Clinical diagnosis is based on medical history, physical examination, laboratory data and imaging. Genetic testing is useful for confirming diagnosis, and for differential diagnosis, recurrence risk evaluation and asymptomatic diagnosis in families with a known mutation. Differential diagnosis should consider the above conditions and secondary causes of thrombosis.

Thrombophilia has autosomal dominant, autosomal recessive, or X-linked inheritance ([Table 1](#T1){ref-type="table"}). Pathogenic variants may be missense, nonsense, splicing or small indels. Large deletions/duplications have been reported in *F5, SERPINC1, PROS1, PROC, F9, FGA*, *FGB*.

###### 

Genes associated with various forms of thrombophilia

  Gene         OMIM gene   Disease                                  OMIM disease     Inheritance   Function
  ------------ ----------- ---------------------------------------- ---------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  *F5*         612309      THPH2                                    188055           AD            Activation of prothrombin to thrombin
  *F2*         176930      THPH1                                    188050           AD            Coagulation and maintenance of vascular integrity
  *SERPINC1*   107300      AT3D                                     613118           AD            Inhibition of thrombin, regulation of blood coagulation cascade
  *HRG*        142640      THPH11                                   613116           AD            Adaptor protein involved in coagulation, fibrinolysis
  *PROS1*      176880      THPH5, THPH6                             612336, 614514   AD, AR        Prevention of coagulation, stimulation of fibrinolysis
  *SERPIND1*   142360      THPH10                                   612356           AD            Thrombin, chymotrypsin inhibitor
  *PROC*       612283      THPH3, THPH4                             176860, 612304   AD, AR        Regulation of blood coagulation by inactivating factors Va and VIIIa
  *F13B*       134580      Deficiency of B subunit of factor XIII   613235           AR            B subunit of factor XIII, stabilizes fibrin clots
  *F9*         300746      THPH8                                    300807           XLR           Activates factor X
  *PLAT*       173370      THPH9                                    612348           AD            Involved in tissue remodeling, degradation
  *THBD*       188040      THPH12                                   614486           AD            Regulation of amount of thrombin
  *FGB*        134830      Congenital dysfibrinogenemia             616004           AD            Beta component of fibrinogen. After vascular injury, fibrinogen is converted into thrombin to form fibrin (major component of blood clots)
  *FGG*        134850      Congenital dysfibrinogenemia             616004           AD            Gamma component of fibrinogen. After vascular injury, fibrinogen is converted into thrombin to form fibrin (major component of blood clots)
  *HABP2*      603924      THPH1                                    188050           AD            Role in coagulation and fibrinolysis systems
  *MTHFR*      607093      THPH1                                    188050           AD            Conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate

THPH=thrombophilia; AT3D=antithrombin III deficiency; AD=autosomal dominant; AR=autosomal recessive; XLR=X-linked recessive

MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes and MLPA to detect duplications and deletions in *F5, SERPINC1, PROS1, PROC, F9, FGA* and *FGB*. Worldwide, 78 accredited medical genetic laboratories in the EU and 27 in the US, listed in the Orphanet ([@ref5]) and GTR ([@ref6]) databases, respectively, offer genetic tests for thrombophilia. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref2]).

Conclusions {#sec1-2}
===========

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with cardiac disorders. When a suspect of thrombophilia is present, we perform the analysis of all the genes present in this short article.

In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of ≥99% (coverage depth ≥10x).
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